SJC, 66 Joint Count | TJC, 68 Joint Count | Patient Global VAS, mm | Physician Global VAS, mm | Patient Pain VAS, mm | CRP, mg/dl | ESR, mm/h | HAQ-DI | |
---|---|---|---|---|---|---|---|---|
Placebo-MTX, n = 393 | ||||||||
n | 391 | 391 | 137 | 139 | 137 | 139 | 139 | 127 |
Mean | −3.5 | −5.9 | −33.2 | −43.9 | −25.6 | −1.6346 | −30.7 | −0.50 |
SD | 11.65 | 17.07 | 26.35 | 21.55 | 24.44 | 2.28001 | 22.26 | 0.612 |
Median | −2.0 | −3.0 | −33.0 | −47.0 | −28.0 | −0.8890 | −30.0 | −0.50 |
Minimum-maximum | −58 to 43 | −65 to 42 | −89 to 29 | −87 to 25 | −78 to 45 | −14.927 to 1.150 | −108 to 30 | −2.3 to 1.4 |
4 mg/kg tocilizumab-MTX, n = 399 | ||||||||
n | 399 | 399 | 228 | 229 | 228 | 231 | 231 | 218 |
Mean | −9.0 | −13.6 | −31.6 | −49.1 | −26.6 | −1.6863 | −35.4 | −0.58 |
SD | 10.76 | 16.53 | 27.05 | 20.33 | 25.39 | 2.20965 | 25.07 | 0.608 |
Median | −8.0 | −13.0 | −32.0 | −50.0 | −26.0 | −1.0820 | −32.0 | −0.50 |
Minimum-maximum | −57 to 21 | −68 to 35 | −100 to 60 | −94 to 22 | −100 to 36 | −12.240 to 5.140 | −117 to 55 | −3.0 to 1.1 |
8 mg/kg tocilizumab-MTX, n = 398 | ||||||||
n | 397 | 397 | 248 | 250 | 248 | 251 | 247 | 231 |
Mean | −11.3 | −17.7 | −33.9 | −48.7 | −28.9 | −2.3068 | −36.9 | −0.61 |
SD | 11.31 | 16.73 | 26.60 | 22.20 | 25.47 | 2.65256 | 23.39 | 0.661 |
Median | −10.0 | −17.0 | −32.5 | −50.0 | −27.0 | −1.5400 | −33.0 | −0.50 |
Minimum-maximum | −62 to 48 | −67 to 48 | −95 to 39 | −97 to 48 | −96 to 34 | −19.281 to 3.359 | −114 to 57 | −2.9 to 1.5 |
Last-observation-carried-forward was used for TJC and SJC; no imputation was used for missing HAQ score, CRP, ESR, and VAS assessments. All assessments were set to missing from the time a patient receives escape therapy, and only pre-escape therapy joint count assessments were carried forward. CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire Disability Index; SJC: swollen joint count; TJC: tender joint count; VAS: visual analog scale; ACR: American College of Rheumatology; MTX: methotrexate.